This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maschek, G. Articles by Lampidis, T. J. Search for Related Content PubMed PubMed Citation Articles by Maschek, G. Articles by Lampidis, T. J.

2-Deoxy-D-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo

¹Department of Cell Biology and Anatomy, University of Miami, School of Medicine and Sylvester Comprehensive Cancer Center, Miami, Florida; ²Hematology/Oncology Section, Department of Medicine, University of Miami School of Medicine, Miami, Florida; ³Department of Bioimmunotherapy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; ⁴Department of Radiation Oncology, University of Miami, School of Medicine and Sylvester Comprehensive Cancer Center, Miami, Florida; ⁵Division of Biostatistics, University of Miami, School of Medicine and Sylvester Comprehensive Cancer Center, Miami, Florida; and ⁶Threshold Pharmaceuticals, South San Francisco, California

Slow-growing cell populations located within solid tumors are difficult to target selectively because most cells in normal tissues also have low replication rates. However, a distinguishing feature between slow-growing normal and tumor cells is the hypoxic microenvironment of the latter, which makes them extraordinarily dependent on anaerobic glycolysis for survival. Previously, we have shown that hypoxic tumor cells exhibit increased sensitivity to inhibitors of glycolysis in three distinct in vitro models. Based on these results, we predicted that combination therapy of a chemotherapeutic agent to target rapidly dividing cells and a glycolytic inhibitor to target slow-growing tumor cells would have better efficacy than either agent alone. Here, we test this strategy in vivo using the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) in combination with Adriamycin (ADR) or paclitaxel in nude mouse xenograft models of human osteosarcoma and non-small cell lung cancer. Nude mice implanted with osteosarcoma cells were divided into four groups as follows: (a) untreated controls; (b) mice treated with ADR alone; (c) mice treated with 2-DG alone; or (d) mice treated with a combination of ADR + 2-DG. Treatment began when tumors were either 50 or 300 mm³ in volume. Starting with small or large tumors, the ADR + 2-DG combination treatment resulted in significantly slower tumor growth (and therefore longer survival) than the control, 2-DG, or ADR treatments (P < 0.0001). Similar beneficial effects of combination treatment were found with 2-DG and paclitaxel in the MV522 non-small cell lung cancer xenograft model. In summary, the treatment of tumors with both the glycolytic inhibitor 2-DG and ADR or paclitaxel results in a significant reduction in tumor growth compared with either agent alone. Overall, these results, combined with our in vitro data, provide a rationale for initiating clinical trials using glycolytic inhibitors in combination with chemotherapeutic agents to increase their therapeutic effectiveness.

This article has been cited by other articles:

				G. P. Lobo, K. A. Waite, S. M. Planchon, T. Romigh, J. A. Houghton, and C. Eng ATP modulates PTEN subcellular localization in multiple cancer cell lines Hum. Mol. Genet., September 15, 2008; 17(18): 2877 - 2885. [Abstract] [Full Text] [PDF]

				H. Boutrid, M.-E. Jockovich, T. G. Murray, Y. Pina, W. J. Feuer, T. J. Lampidis, and C. M. Cebulla Targeting Hypoxia, a Novel Treatment for Advanced Retinoblastoma Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 2799 - 2805. [Abstract] [Full Text] [PDF]

				Y. Wang, Y. Liu, C. Wu, B. McNally, Y. Liu, and P. Zheng Laforin Confers Cancer Resistance to Energy Deprivation-Induced Apoptosis Cancer Res., June 1, 2008; 68(11): 4039 - 4044. [Abstract] [Full Text] [PDF]

				D. Zhong, X. Liu, K. Schafer-Hales, A. I. Marcus, F. R. Khuri, S.-Y. Sun, and W. Zhou 2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition Mol. Cancer Ther., April 1, 2008; 7(4): 809 - 817. [Abstract] [Full Text] [PDF]

				M. Kurtoglu, N. Gao, J. Shang, J. C. Maher, M. A. Lehrman, M. Wangpaichitr, N. Savaraj, A. N. Lane, and T. J. Lampidis Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation Mol. Cancer Ther., November 1, 2007; 6(11): 3049 - 3058. [Abstract] [Full Text] [PDF]

				A. L. Simons, I. M. Ahmad, D. M. Mattson, K. J. Dornfeld, and D. R. Spitz 2-Deoxy-D-Glucose Combined with Cisplatin Enhances Cytotoxicity via Metabolic Oxidative Stress in Human Head and Neck Cancer Cells Cancer Res., April 1, 2007; 67(7): 3364 - 3370. [Abstract] [Full Text] [PDF]

				J. C. Maher, M. Wangpaichitr, N. Savaraj, M. Kurtoglu, and T. J. Lampidis Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose Mol. Cancer Ther., February 1, 2007; 6(2): 732 - 741. [Abstract] [Full Text] [PDF]

				H. Zhang, A. M. Pelzer, D. T. Kiang, and D. Yee Down-regulation of Type I Insulin-like Growth Factor Receptor Increases Sensitivity of Breast Cancer Cells to Insulin Cancer Res., January 1, 2007; 67(1): 391 - 397. [Abstract] [Full Text] [PDF]

				N. Jelluma, X. Yang, D. Stokoe, G. I. Evan, T. B. Dansen, and D. A. Haas-Kogan Glucose Withdrawal Induces Oxidative Stress followed by Apoptosis in Glioblastoma Cells but not in Normal Human Astrocytes Mol. Cancer Res., May 1, 2006; 4(5): 319 - 330. [Abstract] [Full Text] [PDF]

				K. K. Andringa, M. C. Coleman, N. Aykin-Burns, M. J. Hitchler, S. A. Walsh, F. E. Domann, and D. R. Spitz Inhibition of Glutamate Cysteine Ligase Activity Sensitizes Human Breast Cancer Cells to the Toxicity of 2-Deoxy-D-Glucose Cancer Res., February 1, 2006; 66(3): 1605 - 1610. [Abstract] [Full Text] [PDF]

				H. Bando, T. Atsumi, T. Nishio, H. Niwa, S. Mishima, C. Shimizu, N. Yoshioka, R. Bucala, and T. Koike Phosphorylation of the 6-Phosphofructo-2-Kinase/Fructose 2,6-Bisphosphatase/PFKFB3 Family of Glycolytic Regulators in Human Cancer Clin. Cancer Res., August 15, 2005; 11(16): 5784 - 5792. [Abstract] [Full Text] [PDF]

				R.-h. Xu, H. Pelicano, Y. Zhou, J. S. Carew, L. Feng, K. N. Bhalla, M. J. Keating, and P. Huang Inhibition of Glycolysis in Cancer Cells: A Novel Strategy to Overcome Drug Resistance Associated with Mitochondrial Respiratory Defect and Hypoxia Cancer Res., January 15, 2005; 65(2): 613 - 621. [Abstract] [Full Text] [PDF]